Neumora Therapeutics, Inc. (NMRA) — Financial Flexibility Index
Neumora Therapeutics, Inc. (NMRA) has a Financial Flexibility Index of -1.02x as of September 2025. Free cash flow of $-46.62 Million (operating CF $-46.63 Million minus capex $16.00K) represents -1% of total liabilities ($45.67 Million). Check NMRA PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Neumora Therapeutics, Inc. Financial Flexibility Index (2019–2024)
Historical Financial Flexibility Index trend for Neumora Therapeutics, Inc. across 6 annual periods. See working capital position of Neumora Therapeutics, Inc. to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Neumora Therapeutics, Inc. (2019–2024)
Year-by-year free cash flow to debt coverage for Neumora Therapeutics, Inc.. For the full company profile including market capitalisation, see Neumora Therapeutics, Inc. market capitalisation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -6.12x | $-182.94 Million | $-182.94 Million | $29.91 Million | ▼ -1.7% |
| 2023 | -6.02x | $-163.16 Million | $-163.28 Million | $27.12 Million | ▼ -4492.3% |
| 2022 | -0.13x | $-114.39 Million | $-114.90 Million | $873.08 Million | ▼ -32.5% |
| 2021 | -0.10x | $-74.60 Million | $-75.42 Million | $754.52 Million | ▼ -13.5% |
| 2020 | -0.09x | $-25.46 Million | $-26.76 Million | $292.33 Million | ▲ +100.0% |
| 2019 | -1212.38x | $-25.46 Million | $-26.76 Million | $21.00K | — |